Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoonRISe-1 TAR-210 vs intravesical chemotherapy in intermediate-risk non-muscle invasive bladder cancer
jRCT2031240100Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of Erda-iDRS in bladder cancer (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease Free Survival (DFS). Started Sep 2024; status: recruiting.
02
Drugs
Erda-iDRS
03
Conditions
bladder cancer
Beyond the preview
Go deeper on jRCT2031240100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240100.